Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Cancer stem cells also called cancer initiating cells

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Mar 25, 2024 7:13am

74 Views

Post# 35950158

RE:RE:RE:RE:RE:Cancer stem cells also called cancer initiating cells

Yes I think it was reported.

Lee430 wrote: The corporate presentation has been taken down.

https://www.theratech.com/investors/news-events/presentations

Scarlet, Could it be that the BOD & C-suite were somewhat offended by your comments so they marked your post as abusive to get it removed?

I hope the new board member does some good, however, I am a little skeptical as over the years we have had a string of what we thought were going to be saviors only to see them crash, the worst hands down is our unethical and ineffective Chairwoman Dawn Svoronos.

scarlet1967 wrote: I said what I thought about the board and management not long ago and the post was removed. No point to repeat it again but I have a feeling not only individual investors but some other (apart from Soleus) institutional investors share the same views as many many retail investors.

jfm1330 wrote: I have no trust left for this management team, but hey, I am stuck in, so I have to read what they say, not believing them, but at least I take notice of what they say, and in their last PR the say this:

"Our investment in the SORT1+ Technology platform over the past five years has generated important evidence on multiple peptide-drug conjugates with different payloads. Now that we have significantly advanced our preclinical program, we are well positioned to leverage this wealth of data and insights to attract an oncology R&D [research and development] partner."

So they talk about the whole program with preclinical data on many PDCs with different payloads. So if one want to believe them, a positive way to look at this is that they could use TH1902 preclinical and clinical data to extrapolate clinical data of PDCs with more potent payloads, but Thera is unable to start clinical trials on them. The idea is that if TH1902 is yielding good enough clinical data, and they have better preclinical data on other PDCs, they could attract a partner for more than TH1902, but for the whole thing. Obviously, the partner would have most of the rights, and Thera just enough to justify the investment they made in the whole program.